This experiment addresses the critical AD knowledge gap: "What triggers the switch from normal aging to AD?" (ranked #2 in AD Knowledge Gaps with 30 points). Identifying this trigger point could enable prevention rather than treatment.
Normal Aging to Alzheimer's Disease Transition Trigger
Overview
Mermaid diagram (expand to render)
This experiment addresses the critical AD knowledge gap: "What triggers the switch from normal aging to AD?" (ranked #2 in AD Knowledge Gaps with 30 points). Identifying this trigger point could enable prevention rather than treatment.
What is the molecular event that transforms age-related cognitive decline into Alzheimer's disease pathology? Is there a specific threshold or cascade that constitutes the "point of no return"?
Hypothesis
The transition from normal aging to AD is triggered by one or more of the following:
Amyloid threshold crossing — cumulative amyloid burden exceeds a critical point
Tau nucleation — soluble tau transforms into templating aggregates
Microglial dysfunction — protective microglia transition to a damaging phenotype
Metabolic collapse — neuronal energy failure reaches irreversible levels
Synaptic vulnerability threshold — synaptic loss exceeds regenerative capacity
Study Design
Multi-Cohort Longitudinal Study
Recruit participants from three complementary cohorts:
| Cohort | N | Purpose | Timeline | |--------|---|---------|-----------| | Preclinical AD | 500 | Biomarker trajectory before symptoms | 5 years | | Early MCI | 300 | Identify transition events | 3 years | | Normal Aging Control | 200 | Baseline comparison | 5 years |
Inclusion Criteria
Age: 60-85 years
Cognitive status: Normal, MCI, or early AD
Biomarkers: Amyloid PET, tau PET, CSF biomarkers
Exclusion: Known causes of dementia, significant vascular disease
Validation Protocol
Phase 1: Biomarker Baseline and Trajectory (Months 1-24)